These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 20062025)
1. Investor volatility plagues drug companies on new Chinese exchange. Mitchell P; Jing F Nat Biotechnol; 2010 Jan; 28(1):9-10. PubMed ID: 20062025 [No Abstract] [Full Text] [Related]
2. Public companies get creative in raising finance. Hodgson J Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161 [No Abstract] [Full Text] [Related]
3. Gold in the ivory tower: equity rewards of outlicensing. Edwards M; Murray F; Yu R Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129 [TBL] [Abstract][Full Text] [Related]
4. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation. Reed SD; Califf RM; Schulman KA Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727 [TBL] [Abstract][Full Text] [Related]
5. BioXell: an Italian biotech success story? Sheridan C Nat Biotechnol; 2006 Sep; 24(9):1045-6. PubMed ID: 16964198 [No Abstract] [Full Text] [Related]
10. Capital faucet wide-open. Firms' healthcare-related investments up 16% in first half. Pallarito K Mod Healthc; 1997 Sep; 27(35):76. PubMed ID: 10170390 [No Abstract] [Full Text] [Related]